<html><body><h1>Case: 1316243</h1>
77.0 year old Asian_or_Pacific-Islander_Non-Hispanic Male
<p><b>Numeric Data Values:</b> <table>
<b><tr><td width="200">Lab</td><td width="200">Value</td><td width="200">Date</td></tr></b>
<tr><td width="200">Age</td><td width="200">77</td><td width="200">1970-1-1 (2440588)</td></tr>
<tr><td width="200">Calcium</td><td width="200">9</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">Alkaline_phosphatase</td><td width="200">119</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">Glucose</td><td width="200">131</td><td width="200">1975-10-16 (2442702)</td></tr>
<tr><td width="200">Phosphorus</td><td width="200">4</td><td width="200">1979-4-24 (2443988)</td></tr>
<tr><td width="200">LDL_Cholesterol</td><td width="200">49</td><td width="200">1979-2-8 (2443913)</td></tr>
<tr><td width="200">Chloride</td><td width="200">107.0</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">HDL_Cholesterol</td><td width="200">54</td><td width="200">1979-2-8 (2443913)</td></tr>
<tr><td width="200">Diastolic_BP</td><td width="200">75</td><td width="200">1979-6-15 (2444040)</td></tr>
<tr><td width="200">BNP</td><td width="200">2,072</td><td width="200">1979-4-16 (2443980)</td></tr>
<tr><td width="200">B 12</td><td width="200">919.0</td><td width="200">1978-10-26 (2443808)</td></tr>
<tr><td width="200">Weight</td><td width="200">155</td><td width="200">1979-6-15 (2444040)</td></tr>
<tr><td width="200">HbA1C</td><td width="200">6.1</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">Triglycerides</td><td width="200">87</td><td width="200">1979-2-8 (2443913)</td></tr>
<tr><td width="200">Urine_ALB/CREAT_RATIO_spot</td><td width="200">110</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">Urine_Alb/creat_Ratio_24h</td><td width="200">110</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">Total_Cholesterol</td><td width="200">108</td><td width="200">1979-2-8 (2443913)</td></tr>
<tr><td width="200">SGOT</td><td width="200">32</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">Systolic_BP</td><td width="200">132</td><td width="200">1979-6-15 (2444040)</td></tr>
<tr><td width="200">Total_Bilirubin</td><td width="200">1</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">Height</td><td width="200">64</td><td width="200">1979-6-12 (2444037)</td></tr>
<tr><td width="200">Potassium</td><td width="200">3.8</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">Cholesterol</td><td width="200">110</td><td width="200">1979-2-8 (2443913)</td></tr>
<tr><td width="200">BUN</td><td width="200">23</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">HCT</td><td width="200">30</td><td width="200">1979-4-18 (2443982)</td></tr>
<tr><td width="200">HGB</td><td width="200">10</td><td width="200">1979-4-18 (2443982)</td></tr>
<tr><td width="200">Sodium</td><td width="200">141</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">Albumen</td><td width="200">3.6</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">Creatinine</td><td width="200">1.1</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">UrineAlbumin_24H</td><td width="200">170</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">Glycosylated_Hemoglobin</td><td width="200">6.1</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">UrineAlbumin_SPOT</td><td width="200">170</td><td width="200">1979-5-28 (2444022)</td></tr>
<tr><td width="200">Pulse</td><td width="200">72</td><td width="200">1979-6-15 (2444040)</td></tr>
<tr><td width="200">PLT</td><td width="200">130</td><td width="200">1979-4-18 (2443982)</td></tr>
<tr><td width="200">WBC</td><td width="200">6</td><td width="200">1979-4-18 (2443982)</td></tr>
<tr><td width="200">eGFR</td><td width="200">38</td><td width="200">1979-4-24 (2443988)</td></tr>
<tr><td width="200">target_HBA1c</td><td width="200">7.0</td><td width="200">1979-4-30 (2443994)</td></tr>
<tr><td width="200">SGPT</td><td width="200">50</td><td width="200">1979-5-28 (2444022)</td></tr>
</table>
<p><b>Medications:</b> furosemide(25.0[null:0, null]) Insulin(0.05[null:0, null]) metformin(1250.0[null:0, null]) simvastatin(50.0[null:0, null]) tamsulosin(0.5[null:0, null]) terazosin(15.0[null:0, null]) triamterene(20.0[null:0, null]) 
<p><b>Qualitative Data:</b> <table>
<tr><td width="200"><b>Parameter</b></td> <td width="200"><b>Value</b></td><td width="200"><b>Dates</b></td></tr>
<tr><td width="200">Angina</td><td width="200"></td><td width="200">1978-3-27</td></tr>
<tr><td width="200">Asthma</td><td width="200"></td><td width="200">1978-3-27</td></tr>
<tr><td width="200">Atrial Fibrillation</td><td width="200"></td><td width="200">1979-5-16</td></tr>
<tr><td width="200">Cardiomegaly</td><td width="200"></td><td width="200">1978-11-26</td></tr>
<tr><td width="200">Coronary Artery Disease</td><td width="200"></td><td width="200">1979-4-30</td></tr>
<tr><td width="200">Disorders Lipid Metabolism</td><td width="200"></td><td width="200">1978-9-26</td></tr>
<tr><td width="200">Diabetes Type 2</td><td width="200"></td><td width="200">1979-4-30</td></tr>
<tr><td width="200">edema</td><td width="200"></td><td width="200">1978-6-22</td></tr>
<tr><td width="200">Heart Block</td><td width="200"></td><td width="200">1978-6-19</td></tr>
<tr><td width="200">Heart Failure HTN</td><td width="200"></td><td width="200">1979-6-12</td></tr>
<tr><td width="200">Hypertension</td><td width="200"></td><td width="200">1979-3-28</td></tr>
<tr><td width="200">Has Pacemaker</td><td width="200"></td><td width="200">1979-4-16</td></tr>
<tr><td width="200">BPH</td><td width="200"></td><td width="200">1978-7-19</td></tr>
<tr><td width="200">Unspecified AV Block</td><td width="200"></td><td width="200">1979-1-25</td></tr>
<tr><td width="200">Race</td><td width="200">Asian_or_Pacific-Islander_Non-Hispanic</td><td width="200"></td></tr>
<tr><td width="200">Sex</td><td width="200">Male</td><td width="200"></td></tr>
</table><p>
<b>Patient classification:</b> <ul>
<li>VA/JNC-VII Hypertension Guideline: true[because <i> Eligibility criteria </i> evaluate to <b>true</b><i>(null && eGFR(38.0:04/24/1979) && Antihypertensive_Agents(2) && Age(77.0:01/01/1970) && Antihypertensive_Agents(2))</i>]
<li>Risk Group C (presence of TOD/CCD or DM): [because <i> presence of TOD/CCD or DM </i> evaluate to <b>true</b><i>(null)</i>]
</ul>
<b>Scenario choice:</b> on two or three anti-hypertensive drugs
<p>
<b>Goal:</b> SBP < 140 and DBP < 80(presence of diabetes mellitus)
<p><b>Reached goal?</b> achieved(Treatment_Diastolic_BP(75) && Treatment_Systolic_BP(132))
<p><b>Action Choices</b>
<ul>
<li><b>on medication: things to check</b><br>
<ul>
<li><b>assumption  check presence of BP <font color=FF0000>preferred</font></b>(rule in criterion<i> diastolic BP or systolic BP absent</i> evaluate to <b> true</b> )])
[Assumption]We did not find a BP in the vitals signs section of the computer.  We are not at present able to use the BP recorded in the text of the progress note, so we are not able to determine whether the BP control is adequate or inadequate.  Please enter BP using the top part of the screen.
<li><b>adverse event warning <font color=FF0000>preferred</font></b>(rule in criterion<i> presence of current medication with adverse reaction</i> evaluate to <b> true</b> )])
<li><b>alpha blocker orthostasis <font color=FF0000>preferred</font></b>(rule in criterion<i> presence of alpha blocker</i> evaluate to <b> true</b> )])
[Recommendation]This patient has an active prescription for an alpha adrenergic antagonist. We assume that you have checked the patient's standing blood pressure and that the patient does not have orthostasis (for example, SBP drop >20 mmHg).
<li><b>test parameterized message <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</b> )])
[Recommendation]It is false that 7.3 inches of rain fell yesterday, and the patient is taking the following drugs: furosemide, Insulin, simvastatin, tamsulosin, terazosin, triamterene
<li><b>Check for medications above upper limit <font color=FF0000>preferred</font></b>(rule in criterion<i> there exists a medication whose dose is over the upper limit</i> evaluate to <b> true</b> )])
[Primary_Recommendation]The dose of terazosin is above the upper limit for management of hypertension. Please check if prescription information is accurate.
<li><b>Disclaimer <font color=FF0000>preferred</font></b>(rule in criterion<i> true</i> evaluate to <b> true</b> )])
[Recommendation]The clinical information from this system is advisory only and is intended to supplement the knowledge of health care professionals regarding the management of hypertension. It is not intended to replace sound clinical judgment or individualized patient care in delivery of healthcare services.
  Although the ATHENA-HTN information is derived from research literature and is subject to review, we cannot guarantee its comprehensiveness or currency. Please note that medical information is dynamic due to ongoing research and clinical experience and is subject to interpretation. There is also the possibility of errors in the programming.  The user of this software assumes sole responsibility for any decisions made or actions taken based the information contained in this software, including but not limited to therapeutic suggestions.  ATHENA-HTN, the Department of Veterans Affairs and Stanford University shall have no liability to any person, or entity with regard to claims, loss, or damage caused, or alleged to be caused, directly or indirectly by the use of this software or the information contained within.  ATHENA-HTN is the property of Stanford's Office Technology Licensing (OTL) and Department of Veterans Affairs.  
By accessing ATHENA-HTN, you agree use ATHENA-HTN only as a reference resource for research. You agree to abstain from using ATHENA-HTN to generate knowledge for treatment.
</ul>
<li><b>two or three drug-therapy choices</b><br>
<ul>
<li><b>on two or three drugs, consider substituting one <font color=FF0000>preferred</font></b>(strict rule-in condition<i> No constraindicated drug and (BP adequately controlled but compellingly indicated drug not given) </i> evaluate to <b> true</b> because <i>Treatment_Diastolic_BP(75) && Treatment_Systolic_BP(132) && null && (~B)no current drug contraindicatednull</i>)])
[Primary_Recommendation]Based on most recent BP in the database, BP appears to be adequately controlled; however, ALTERNATIVE DRUGS may be preferred.

</ul>
<li><b>substitution messages</b><br>
<ul>
<li><b>NO ADE recommended drug SUB <font color=FF0000>preferred</font></b>(rule in criterion<i> there exists recommended drug and none has ADE</i> evaluate to <b> true</b> )])
[Recommendation]No adverse reactions are listed for the antihypertensive drug(s) we are recommending.  If the patient has had an adverse reaction, please enter it in a progress note entitled "Adverse Reactions/Allergy".
</ul>
</ul>
<b>Considerations for substituting drug: </b><ul>
<li> Substitution: replace 
<ul>
<li>tamsulosin(tamsulosin)
<ul>
<li>No comment
</ul>
<li>triamterene(Potassium-Sparing_Diuretics)
<ul>
<li>No comment
</ul>
 with <li>ACE Inhibitor 
<ul>
<li>preferred drug: lisinopril</li>
<li>Bad drug partner:  Potassium-Sparing_Diuretics(triamterene) 
<li><font color=FF0000>Compelling indications:  Heart_Failure(Cardiomegaly, Heart_Failure)  Heart Failure  (Secondary Prev) BP controlled(Heart Failure (Secondary Prevention)[Treatment_Diastolic_BP(75) && Treatment_Systolic_BP(132)])  Diabetes_Mellitus(DM-Type2)  DM (2ary prev)  BP controlled(Diabetes (Secondary Prevention)[Treatment_Diastolic_BP(75) && Treatment_Systolic_BP(132)])  CKD by eGFR or ICD9 codes(CKD by eGFR or ICD9 codes[eGFR(38.0:04/24/1979)]) </font>
<li>Relative contraindications:  Presence of K sparing diuretics(K sparing diuretics[null]) 
<li>[Recommendation] Use of ACE inhibitors in patients with heart failure and ejection fraction <0.35 significantly reduces overall mortality and hospital admissions.  For patients with ejection fraction >=0.35 ACE inhibitors may be beneficial but this is not established.
<li>[Recommendation] When adding ACE inhibitor to this patient's therapeutic regime a dose adjustment of other anti-hypertensive drugs may be required.
<li>[Recommendation] Check the patient's creatinine and potassium concentrations when prescribing  ACE Inhibitors.
<li>[Recommendation] A stable increase of serum creatinine as much as 35% above baseline after ACEI or ARB initiation may be tolerated, as long as hyperkalemia does not occur. ACEI or ARB should be discontinued, or other potentially reversible causes of kidney failure investigated if progressive and rapid rise of serum creatinine continues. Since CKD is associated with progressive rise in creatinine over years, ACEI or ARB should not be discontinued for this situation, since these medications are renoprotective.
<li>preference: ruled out
</ul>
<li>Alpha Blocker 
<ul>
<li>preferred drug: terazosin</li>
<li>Already being used
<li>[Recommendation] To decrease the likelihood of syncope or excessive hypotension treatment should usually be initiated with a dose of 1 or 2 mgs at bedtime. The dose should be increased in a stepwise fashion. Blood pressures should be measured to check for postural drop.
<li>[Recommendation] Compellingly indicated if the patient has symptomatic BPH.
<li>preference: ruled out
</ul>
<li>Cardioselective Beta Blocker 
<ul>
<li>preferred drug: atenolol</li>
<li><font color=FF0000>Compelling indications:  Heart_Failure(Cardiomegaly, Heart_Failure)  Heart Failure (second prev) BP cont(Heart Failure (Secondary prevention)[Treatment_Diastolic_BP(75) && Treatment_Systolic_BP(132)]) </font>
<li>Relative indications:  Angina(Angina)  Atrial_Fibrillation(Atrial_Fibrillation)  Coronary_Artery_Disease(Coronary_Artery_Disease)  CKD by eGFR or ICD9 codes(CKD by eGFR or ICD9 codes[eGFR(38.0:04/24/1979)])  Diabetes_Mellitus(DM-Type2) 
<li>[Recommendation] Beta blockers may diminish symptoms of and recovery from hypoglycemia and should be used with caution in patients who are prone to hypoglycemia.
<li>[Recommendation] Management of  arrythmia is complex and may require consultation with specialist.
<li>[Recommendation] Beta blockers may have transient adverse effects on lipids in some patients.  Consider repeating lipid profile after maximal dosage of drug has been reached if appropriate.
<li>[Recommendation] Diagnoses from EKG reports are not extracted. If patient has an arrythmia that is not shown in patient summary, please update problem list.
<li>[Recommendation] If patient has proteinuria or renal manifestations of diabetes therapy with ACE inhibitor is strongly recommended.
<li>preference: preferred
</ul>
<li>DHP Calcium Channel Blocker 
<ul>
<li>preferred drug: felodipine, nifedipine SA</li>
<li>Relative indications:  Angina(Angina)  Diabetes_Mellitus(DM-Type2) 
<li>[Recommendation] Felodipine is not FDA-Approved for the indication of angina, but by VA guidelines it is the DHP calcium channel antagonist of choice.
<li>preference: neutral
</ul>
<li>(non-DHP) Calcium Channel Blocker 
<ul>
<li>preferred drug: diltiazem</li>
<li>Relative indications:  Atrial_Fibrillation(Atrial_Fibrillation)  Angina(Angina)  CKD by eGFR or ICD9 codes(CKD by eGFR or ICD9 codes[eGFR(38.0:04/24/1979)]) 
<li>Relative contraindications:  Heart_Block_2nd_Or_3rd_Degree(Unspecified AV Block, Heart_Block_2nd_Or_3rd_Degree)  Heart_Failure(Cardiomegaly, Heart_Failure) 
<li>[Recommendation] Patient has heart failure which is a relative contraindication to diltiazem. Evaluate potential benefit versus harm of initiating diltiazem. Follow clinically.
<li>[Recommendation] Patient has heart block which is a relative contraindication to diltiazem. Evaluate potential benefit versus harm of initiating diltiazem. Follow clinically.
<li>[Recommendation] Management of  arrythmia is complex and may require consultation with specialist.
<li>[Recommendation] Diagnoses from EKG reports are not extracted. If patient has an arrythmia that is not shown in patient summary, please update problem list.
<li>preference: neutral
</ul>
<li>Thiazide Diuretic 
<ul>
<li>preferred drug: HCTZ</li>
<li>Bad drug partner:  furosemide(furosemide) 
<li><font color=FF0000>Compelling indications:  CKD by eGFR or ICD9 codes(CKD by eGFR or ICD9 codes[eGFR(38.0:04/24/1979)])  taking >= 2 anti hypertensive meds(Combination therapy for HTN[Antihypertensive_Agents(2)])  Diabetes_Mellitus(DM-Type2) </font>
<li>[Recommendation] HCTZ dose above 25 mg doesn't add to BP control for most patients and may lead to hypokalemia.
<li>[Recommendation] If patient has proteinuria or renal manifestations of diabetes therapy with ACE inhibitor is strongly recommended.
<li>[Recommendation] There is little information about the likelihood that introduction of low-dose thiazides will adversely affect bladder function.  Follow individual patient response to treatment.
<li>preference: ruled out
</ul>
</ul>

</ul>
